Brokerages Set Outset Medical, Inc. (NASDAQ:OM) Target Price at $10.00

Shares of Outset Medical, Inc. (NASDAQ:OM) have been assigned a consensus rating of “Moderate Buy” from the five analysts that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, two have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $10.00.

Several research firms have recently commented on OM. Wall Street Zen lowered shares of Outset Medical from a “hold” rating to a “sell” rating in a research report on Saturday, April 11th. Stifel Nicolaus reduced their price target on shares of Outset Medical from $14.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, January 7th. Weiss Ratings reissued a “sell (e+)” rating on shares of Outset Medical in a research report on Friday, March 27th. Finally, BTIG Research cut their target price on Outset Medical from $17.00 to $15.00 and set a “buy” rating on the stock in a research report on Thursday, February 12th.

Outset Medical Trading Up 1.1%

OM stock opened at $4.40 on Friday. The company has a current ratio of 6.67, a quick ratio of 5.40 and a debt-to-equity ratio of 0.76. Outset Medical has a 12-month low of $3.00 and a 12-month high of $21.98. The stock has a market cap of $80.56 million, a price-to-earnings ratio of -0.65 and a beta of 1.97. The business’s 50-day moving average is $3.71 and its 200 day moving average is $6.24.

Insider Buying and Selling at Outset Medical

In other Outset Medical news, CEO Leslie Trigg sold 11,794 shares of the business’s stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $5.12, for a total value of $60,385.28. Following the completion of the transaction, the chief executive officer owned 107,823 shares in the company, valued at $552,053.76. The trade was a 9.86% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, General Counsel John L. Brottem sold 9,314 shares of the business’s stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $5.12, for a total transaction of $47,687.68. Following the completion of the transaction, the general counsel owned 36,957 shares of the company’s stock, valued at approximately $189,219.84. This trade represents a 20.13% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 38,783 shares of company stock valued at $183,958 over the last quarter. 2.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On Outset Medical

Institutional investors and hedge funds have recently modified their holdings of the company. Assenagon Asset Management S.A. acquired a new position in shares of Outset Medical during the third quarter worth $5,324,000. Birchview Capital LP grew its stake in shares of Outset Medical by 40.7% during the second quarter. Birchview Capital LP now owns 34,584 shares of the company’s stock worth $664,000 after purchasing an additional 10,000 shares in the last quarter. Walleye Capital LLC acquired a new position in shares of Outset Medical during the second quarter worth $1,078,000. Jain Global LLC acquired a new position in shares of Outset Medical during the fourth quarter worth $78,000. Finally, Wells Fargo & Company MN grew its stake in shares of Outset Medical by 57.0% during the fourth quarter. Wells Fargo & Company MN now owns 18,271 shares of the company’s stock worth $68,000 after purchasing an additional 6,632 shares in the last quarter.

Outset Medical Company Profile

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.